ଆସ୍କିମିନିବ

ଆସ୍କିମିନିବ
Clinical data
Trade names	Scemblix
Synonyms	ABL001
AHFS/Drugs.com	monograph
data	US DailyMed: Asciminib;
Pregnancy; category	AU: D ; ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; US: ℞-only ; EU: Rx-only ;
Identifiers
	IUPAC name N-4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide;hydrochloride;
Chemical and physical data
Formula	C20H18ClF2N5O3
Molar mass	୪୪୯.୮୪ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2ccn[nH]2)c1;
	InChI InChI=1S/C20H18ClF2N5O3/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30)/t14-/m1/s1; Key:VOVZXURTCKPRDQ-CQSZACIVSA-N;

ଆସ୍କିମିନିବ (ଇଂରାଜୀ ଭାଷାରେ Asciminib) , Scemblix ଏହାର ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଫିଲାଡେଲଫିଆ କ୍ରୋମୋଜୋମ-ପଜିଟିଭ୍ (Ph + CML) ଥିବା କ୍ରନିକ୍ ମାଇଲୋଏଡ୍ ଲ୍ୟୁକେମିଆର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୪] ^[୩] ଯେତେବେଳେ ଅନ୍ୟ ଔଷଧ ବିଫଳ ହୁଏ, ସେତେବେଳେ ଏହା ବ୍ୟବହୃତ ହୁଏ ।^[୩] ଏହାକୁ ଦିନକୁ ଦୁଇଥର ପାଟିରେ ଦିଆଯାଏ ।^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଉର୍ଦ୍ଦ୍ୱ ଶ୍ୱାସନଳୀ ସଂକ୍ରମଣ, ଅସ୍ଥି- ମାଂସପେଶୀ ଯନ୍ତ୍ରଣା, ମୁଣ୍ଡବିନ୍ଧା, ଥକାପଣ, ଅଇ, ରାସ ଏବଂ ତରଳ ଝାଡ଼ା ହୋଇପାରେ । ^[୪] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅସ୍ଥି ମଜ୍ଜା ଦମନ, ଅଗ୍ନାଶୟ ପ୍ରଦାହ, ଉଚ୍ଚ ରକ୍ତଚାପ, ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା ଏବଂ ହୃଦରୋଗ ହୋଇପାରେ ।^[୪] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୪] ଏହା ଏକ ଟାଇରୋସିନ କାଇନେଜ ଇନହିବିଟର, ବିଶେଷ ଭାବରେ ବିସିଆର-ଏବିଏଲ୧ (BCR :: ABL1) ଟାଇରୋସିନ କାଇନେଜର । ^[୩]

୨୦୨୧ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୨୨ରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଆସ୍କିମିନିବକୁ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୪] ^[୩] ଯୁକ୍ତରାଜ୍ୟରେ ଏହି ଔଷଧ ଦିନକୁ ଦୁଇଥର, ଥରକୁ ୪୦ ମିଗ୍ରା ଭାବରେ ୩୦ ଦିନ ଦେଲେ ୪୦୪୫ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୁଏ ।^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୧୮,୫୦୦ ଡଲାର ଅଟେ ।^[୬]

ଆଧାର ସମ୍ପାଦନା

↑ ^୧.୦ ^୧.୧ "Scemblix APMDS". Therapeutic Goods Administration (TGA). 26 July 2022. Archived from the original on 2 August 2022. Retrieved 2 August 2022.
↑ "Scemblix Product information". Health Canada. Archived from the original on 1 October 2022. Retrieved 30 September 2022.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ "Scemblix EPAR". European Medicines Agency (EMA). 20 June 2022. Archived from the original on 9 September 2022. Retrieved 8 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ "Scemblix- asciminib tablet, film coated". DailyMed. Archived from the original on 5 November 2021. Retrieved 4 November 2021.
↑ "Asciminib". SPS - Specialist Pharmacy Service. 20 March 2018. Archived from the original on 3 March 2022. Retrieved 25 October 2022.
↑ "Scemblix". Archived from the original on 25 October 2022. Retrieved 25 October 2022.

[Scemblix_APMDS-1] ୧.୦ ^୧.୧ "Scemblix APMDS". Therapeutic Goods Administration (TGA). 26 July 2022. Archived from the original on 2 August 2022. Retrieved 2 August 2022.

[2] "Scemblix Product information". Health Canada. Archived from the original on 1 October 2022. Retrieved 30 September 2022.

[EPAR2022-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ "Scemblix EPAR". European Medicines Agency (EMA). 20 June 2022. Archived from the original on 9 September 2022. Retrieved 8 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[PI2022-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ "Scemblix- asciminib tablet, film coated". DailyMed. Archived from the original on 5 November 2021. Retrieved 4 November 2021.

[5] "Asciminib". SPS - Specialist Pharmacy Service. 20 March 2018. Archived from the original on 3 March 2022. Retrieved 25 October 2022.

[6] "Scemblix". Archived from the original on 25 October 2022. Retrieved 25 October 2022.

[୪]

[୩]

[୧]

[୨]

[୫]

[୬]